Literature DB >> 29309555

Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.

Abraham S Meijnikman1,2, Victor E Gerdes1,2, Max Nieuwdorp1,3,4,5,6, Hilde Herrema1.   

Abstract

The pathophysiology of obesity and obesity-related diseases such as type 2 diabetes mellitus (T2DM) is complex and driven by many factors. One of the most recently identified factors in development of these metabolic pathologies is the gut microbiota. The introduction of affordable, high-throughput sequencing technologies has substantially expanded our understanding of the role of the gut microbiome in modulation of host metabolism and (cardio)metabolic disease development. Nevertheless, evidence for a role of the gut microbiome as a causal, driving factor in disease development mainly originates from studies in mouse models: data showing causality in humans are scarce. In this review, we will discuss the quality of evidence supporting a causal role for the gut microbiome in the development of obesity and diabetes, in particular T2DM, in humans. Considering overlap in potential mechanisms, the role of the gut microbiome in type 1 diabetes mellitus will also be addressed. We will elaborate on factors that drive microbiome composition in humans and discuss how alterations in microbial composition or microbial metabolite production contribute to disease development. Challenging aspects in determining causality in humans will be postulated together with strategies that might hold potential to overcome these challenges. Furthermore, we will discuss means to modify gut microbiome composition in humans to help establish causality and discuss systems biology approaches that might hold the key to unravelling the role of the gut microbiome in obesity and T2DM.

Entities:  

Mesh:

Year:  2018        PMID: 29309555     DOI: 10.1210/er.2017-00192

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  76 in total

1.  Nanosilver Mitigates Biofilm Formation via FapC Amyloidosis Inhibition.

Authors:  Zil-E Huma; Ibrahim Javed; Zhenzhen Zhang; Hajira Bilal; Yunxiang Sun; Syed Zajif Hussain; Thomas P Davis; Daniel E Otzen; Cornelia B Landersdorfer; Feng Ding; Irshad Hussain; Pu Chun Ke
Journal:  Small       Date:  2020-01-27       Impact factor: 13.281

2.  Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity: a pilot study.

Authors:  Federica Del Chierico; Melania Manco; Simone Gardini; Valerio Guarrasi; Alessandra Russo; Marzia Bianchi; Valentina Tortosa; Andrea Quagliariello; Blegina Shashaj; Danilo Fintini; Lorenza Putignani
Journal:  Acta Diabetol       Date:  2021-03-22       Impact factor: 4.280

3.  Nonnutritive sweetener consumption during pregnancy, adiposity, and adipocyte differentiation in offspring: evidence from humans, mice, and cells.

Authors:  Meghan B Azad; Alyssa Archibald; Mateusz M Tomczyk; Alanna Head; Kyle G Cheung; Russell J de Souza; Allan B Becker; Piushkumar J Mandhane; Stuart E Turvey; Theo J Moraes; Malcolm R Sears; Padmaja Subbarao; Vernon W Dolinsky
Journal:  Int J Obes (Lond)       Date:  2020-05-04       Impact factor: 5.095

4.  Early Signs of Gut Microbiome Aging: Biomarkers of Inflammation, Metabolism, and Macromolecular Damage in Young Adulthood.

Authors:  Audrey Renson; Kathleen Mullan Harris; Jennifer B Dowd; Lauren Gaydosh; Matthew B McQueen; Kenneth S Krauter; Michael Shannahan; Allison E Aiello
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-06-18       Impact factor: 6.053

Review 5.  Gut microbiota-derived metabolites in CRC progression and causation.

Authors:  Nishu Dalal; Rekha Jalandra; Nitin Bayal; Amit K Yadav; Minakshi Sharma; Govind K Makharia; Pramod Kumar; Rajeev Singh; Pratima R Solanki; Anil Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-17       Impact factor: 4.553

6.  Long-term use of antibiotics and risk of type 2 diabetes in women: a prospective cohort study.

Authors:  Jinqiu Yuan; Yanhong Jessika Hu; Jie Zheng; Jean Hee Kim; Tim Sumerlin; Youpeng Chen; Yulong He; Changhua Zhang; Jinling Tang; Yihang Pan; Michael Moore
Journal:  Int J Epidemiol       Date:  2020-10-01       Impact factor: 7.196

7.  Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice.

Authors:  Yu Du; Xingxing Li; Chunyan Su; Mei Xi; Xiumin Zhang; Zhibo Jiang; Li Wang; Bin Hong
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

Review 8.  Half a century of amyloids: past, present and future.

Authors:  Pu Chun Ke; Ruhong Zhou; Louise C Serpell; Roland Riek; Tuomas P J Knowles; Hilal A Lashuel; Ehud Gazit; Ian W Hamley; Thomas P Davis; Marcus Fändrich; Daniel Erik Otzen; Matthew R Chapman; Christopher M Dobson; David S Eisenberg; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2020-07-07       Impact factor: 54.564

Review 9.  Gut Microbiota-Derived Short-Chain Fatty Acids Facilitate Microbiota:Host Cross talk and Modulate Obesity and Hypertension.

Authors:  Haley B Overby; Jane F Ferguson
Journal:  Curr Hypertens Rep       Date:  2021-02-03       Impact factor: 5.369

10.  Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial.

Authors:  Valentin Mocanu; Zhengxiao Zhang; Edward C Deehan; Dina H Kao; Naomi Hotte; Shahzeer Karmali; Daniel W Birch; Kalutota K Samarasinghe; Jens Walter; Karen L Madsen
Journal:  Nat Med       Date:  2021-07-05       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.